Cachexia - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cachexia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cachexia - Pipeline Review, H1 2015', provides an overview of the Cachexia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cachexia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cachexia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cachexia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cachexia Overview 8
Therapeutics Development 9
Pipeline Products for Cachexia - Overview 9
Pipeline Products for Cachexia - Comparative Analysis 10
Cachexia - Therapeutics under Development by Companies 11
Cachexia - Therapeutics under Investigation by Universities/Institutes 12
Cachexia - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Cachexia - Products under Development by Companies 15
Cachexia - Products under Investigation by Universities/Institutes 16
Cachexia - Companies Involved in Therapeutics Development 17
Aphios Corporation 17
AVEO Pharmaceuticals, Inc. 18
BioLineRx, Ltd. 19
Calzada Limited 20
Cytokinetics, Inc. 21
GlaxoSmithKline plc 22
MI.TO. Technology S.r.L. 23
Myos Corporation 24
Novartis AG 25
Palatin Technologies, Inc. 26
Pfizer Inc. 27
Rhythm Pharmaceuticals 28
Cachexia - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
AOD-9604 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AV-380 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
bimagrumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BL-5040 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CK-2066260 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DLN-101 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
dronabinol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Drugs to Inhibit Activin Receptor for Cachexia - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PF-06260414 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Protein for Musculoskeletal Disorders - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
relamorelin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecules to Inhibit JAK3 for Sarcopenia and Cachexia - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Modulate Melanocortin-4 Receptor for Cachexia - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Synthetic Peptide to Antagonize MC3 and MC4 Receptor for Cachexia - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cachexia - Recent Pipeline Updates 58
Cachexia - Dormant Projects 63
Cachexia - Discontinued Products 64
Cachexia - Product Development Milestones 65
Featured News & Press Releases 65
Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 65
Jun 04, 2002: Aphios Receives National Cancer Institute Grant For Developing Natural Cannabinoid Products for Medical Use 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development for Cachexia, H1 2015 9
Number of Products under Development for Cachexia - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Cachexia - Pipeline by Aphios Corporation, H1 2015 17
Cachexia - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 18
Cachexia - Pipeline by BioLineRx, Ltd., H1 2015 19
Cachexia - Pipeline by Calzada Limited, H1 2015 20
Cachexia - Pipeline by Cytokinetics, Inc., H1 2015 21
Cachexia - Pipeline by GlaxoSmithKline plc, H1 2015 22
Cachexia - Pipeline by MI.TO. Technology S.r.L., H1 2015 23
Cachexia - Pipeline by Myos Corporation, H1 2015 24
Cachexia - Pipeline by Novartis AG, H1 2015 25
Cachexia - Pipeline by Palatin Technologies, Inc., H1 2015 26
Cachexia - Pipeline by Pfizer Inc., H1 2015 27
Cachexia - Pipeline by Rhythm Pharmaceuticals, H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Cachexia Therapeutics - Recent Pipeline Updates, H1 2015 58
Cachexia - Dormant Projects, H1 2015 63
Cachexia - Discontinued Products, H1 2015 64